Igenesis

Igenesis (Shanghai) Co., Ltd. (hereinafter referred to as "Igenesis") was established in 2015. The founder has successful entrepreneurial experience in both Silicon Valley, USA, and mainland China. The core technical team has many years of R&D experience in the field of molecular diagnostics. The company's headquarters is located in the Shanghai International Medical Park, with a current R&D and production area of approximately 3,000 square meters, and a research and development center on Guangzhou International Bio Island. Its business scope covers various regions across China. Igenesis has applied for 66 patents for its developed products, with 44 granted, including 9 authorized inventions. Additionally, the company has obtained 8 software copyrights. The self-developed products Galaxy Nano Fully Automatic Fully Sealed Fluorescence PCR Integrated Machine (POCT model), Galaxy Pro Fully Automatic Fully Sealed Fluorescence PCR Integrated Machine (high-throughput model for 12 samples at once), and the SARS-CoV-2 (2019-nCoV) Nucleic Acid Detection Smart Box (fluorescence RT-PCR method) have all received EU CE certification. The Universal Nano Nucleic Acid Amplification Analyzer has obtained a Class III medical device registration certificate. The innovative molecular diagnostic technology and products have gained high recognition from the Chinese government. On May 16, 2018, Igenesis officially signed up for the National "13th Five-Year Plan" Major Project, with the IGS TB/RIF Lite product participating in the evaluation. During the COVID-19 prevention and control in 2020, Igenesis was listed by the Shanghai government as an "emergency requisition unit for production capacity." The company’s instant molecular diagnostic platform and COVID-19 test kits stood out during the epidemic prevention efforts.Igenesis focuses on instant molecular diagnostic technology and has successfully developed a series of fully automated testing instruments, reagents, and smart reagent boxes suitable for microbial detection, personalized medication genetic testing, cancer detection, forensic evidence, and food safety. Its self-developed fully automatic fully sealed fluorescence PCR analysis system aligns with the global molecular diagnostics trend of "Sample in, Results Out." As a representative of the new generation of PCR technology platforms, it holds technological advantages and market competitiveness and is widely used in medical institutions at all levels, CDCs at all levels, third-party clinical testing institutions, forensic centers, inspection and quarantine bureaus, military epidemic prevention systems, etc.